MHRA launches new programme to tackle gaps in women’s health research

Women Healthcare and Gynecology Wellness Concept.
image: ©Pakorn Supajitsoontorn | iStock

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched a new programme to address longstanding gaps in women’s health research and improve the evidence available on medicines and medical devices

The Women’s Health Programme, announced on 16 November 2026, aims to ensure women are better represented in clinical research and that the potential risks and benefits of treatments are better understood.

Despite women making up 51% of the UK population, there has always been an underrepresentation in medical research. This has contributed to a lack of evidence about how medicines and medical devices affect women, particularly during pregnancy, breastfeeding and different stages of reproductive health.

Gaps in clinical research

An MHRA analysis of 4,616 UK clinical trial applications submitted between 2019 and 2023 highlighted the scale of the problem.

The findings showed that pregnant women were represented in just 1.1% of clinical trials, while breastfeeding women accounted for only 0.6%.

These gaps can make it harder for healthcare professionals and patients to make informed decisions about treatments, as there is often limited evidence about their safety and effectiveness for women.

The Women’s Health Programme will explore how improved data and scientific developments can help build a stronger understanding of women’s health needs. It will also consider how factors such as age, biology, pregnancy and existing health conditions can influence how women respond to medicines and medical devices.

Supporting innovation in women’s health

Alongside improving research, the programme aims to encourage innovation and support the development of new products designed around women’s health needs.

The UK’s FemTech sector is already growing rapidly, with annual turnover approaching £300 million. Innovation is taking place across areas including reproductive health, long-term conditions and healthy ageing.

By working more closely with researchers and innovators early on, the MHRA hopes to support promising products through development and help bring them to patients sooner, while maintaining standards of safety, quality and effectiveness.

Putting women at the centre of research

Patients, researchers, healthcare professionals and industry representatives will all contribute to the programme, which has been shaped with input from the MHRA’s Patient and Public Community and a focus group organised by the Patients Association.

The initiative also supports wider efforts to make clinical research more inclusive. Joint guidance from the MHRA and Health Research Authority provides a framework for researchers to develop Inclusion and Diversity Plans, helping ensure studies better reflect the people who may ultimately benefit from new treatments.

The Women’s Health Programme is part of the MHRA’s 2030 Strategy and contributes to the government’s renewed Women’s Health Strategy for England, alongside related work across Scotland, Wales and Northern Ireland.

Author: Health Watch Minute

Health Watch Minute Provides the latest health information, from around the globe.

Leave a Reply

Your email address will not be published. Required fields are marked *